BioSig Technologies' Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel

Core Insights - BioSig Technologies, Inc. successfully appealed to the NASDAQ Panel, allowing its common stock to resume trading on the NASDAQ Capital Market Exchange starting October 23, 2024 [1] - The company received an extension until March 7, 2025, providing a 360-day grace period for compliance with the Market Value of Listed Securities requirement [1] Company Overview - BioSig Technologies is a medical technology company focused on enhancing the accuracy of intra-cardiac signal visualization, particularly in heart rhythms [2] - The company utilizes a unique software platform to provide clear cardiac signal clarity, addressing significant healthcare challenges such as time, cost, and life-saving measures [2] Product Information - The FDA 510(k) cleared PURE EP™ Platform offers superior real-time signal visualization, enabling physicians to conduct targeted cardiac ablation procedures with improved efficiency and efficacy [3]